Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom s Q1 Revenues Surge, Losses Halved

This article has been updated from a previous version, which had the incorrect percentage increase in the first paragraph.

 

NEW YORK, May 5 (GenomeWeb News) - Sequenom yesterday reported a 61-percent jump in first-quarter revenues and a dramatic reduction in net losses.

 

For the quarter ended March 31, Sequenom's revenues increased to $6.9 million from $4.3 million in the first quarter of 2005.

 

The company's net loss for the first quarter was $3.7 million, or $.09 per share, compared to $7.4 million, or $.19 per share for the first quarter of 2005.

 

Sequenom cut its R&D spending to $2.5 million from $3.3 million in the first quarter of 2005.

 

On March 31, the company had available cash and short-term investments of $2.9 million.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.